Afficher la couverture '2,6-Diaminopurine as a highly potent corrector of UGA nonsense mutations | Trzaska, Carole' en grand format
/5

0 avis

2,6-Diaminopurine as a highly potent corrector of UGA nonsense mutations

Archive ouverte

Trzaska, Carole | Amand, Séverine | Bailly, Christine | Leroy, Catherine | Marchand, Virginie | Duvernois-Berthet, Evelyne | Saliou, Jean-Michel | Benhabiles, Hana | Werkmeister, Elisabeth | Chassat, Thierry | Guilbert, Romain | Hannebique, David | Mouray, Anthony | Copin, Marie-Christine | Moreau, Pierre-Arthur | Adriaenssens, Eric | Kulozik, Andreas | Westhof, Eric | Tulasne, David | Motorin, Yuri | Rebuffat, Sylvie | Lejeune, Fabrice

Edité par CCSD ; Nature Publishing Group -

International audience. Nonsense mutations cause about 10% of genetic disease cases, and no treatments are available. Nonsense mutations can be corrected by molecules with nonsense mutation readthrough activity. An extract of the mushroom Lepista inversa has recently shown high-efficiency correction of UGA and UAA nonsense mutations. One active constituent of this extract is 2,6-diaminopurine (DAP). In Calu-6 cancer cells, in which TP53 gene has a UGA nonsense mutation, DAP treatment increases p53 level. It also decreases the growth of tumors arising from Calu-6 cells injected into immunodeficient nude mice. DAP acts by interfering with the activity of a tRNA-specific 2'-O-methyltransferase (FTSJ1) responsible for cytosine 34 modification in tRNATrp. Low-toxicity and high-efficiency UGA nonsense mutation correction make DAP a good candidate for the development of treatments for genetic diseases caused by nonsense mutations.

Suggestions

Du même auteur

Use of 2,6-diaminopurine as a potent suppressor of UGA premature stop codons in cystic fibrosis

Archive ouverte | Leroy, Catherine | CCSD

International audience. Nonsense mutations are responsible for around 10% of cases of genetic diseases, including cystic fibrosis. 2,6-diaminopurine (DAP) has recently been shown to promote efficient readthrough of ...

Optimized approach for the identification of highly efficient correctors of nonsense mutations in human diseases

Archive ouverte | Benhabiles, Hana | CCSD

International audience. About 10% of patients with a genetic disease carry a nonsense mutation causing their pathology. A strategy for correcting nonsense mutations is premature termination codon (PTC) readthrough, ...

PTC readthrough in human cells occurs in novel cytoplasmic foci and requires UPF proteins

Archive ouverte | Jia, Jieshuang | CCSD

International audience. Nonsense-mutation-containing messenger ribonucleoprotein particles (mRNPs) transit through cytoplasmic foci called P-bodies before undergoing nonsense-mediated mRNA decay (NMD), a cytoplasmic...

Chargement des enrichissements...